About Pulmatrix
Pulmatrix is a company based in Lexington (United States) founded in 2003. Pulmatrix has raised $67.11 million across 19 funding rounds from investors including NIH, HHS and DARPA. The company has 2 employees as of December 31, 2024. Pulmatrix offers products and services including iSPERSE™, PUR3100, PUR1900, and PUR1800. Pulmatrix operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Verona Pharma, among others.
- Headquarter Lexington, United States
- Employees 2 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pulmatrix, Inc.
-
Annual Revenue
$7.81 M (USD)6.96as on Dec 31, 2024
-
Net Profit
-$9.56 M (USD)32.31as on Dec 31, 2024
-
EBITDA
-$6.71 M (USD)49.42as on Dec 31, 2024
-
Total Equity Funding
$67.11 M (USD)
in 19 rounds
-
Latest Funding Round
$45 K (USD), Post-IPO
Jul 09, 2020
-
Investors
NIH
& 9 more
-
Employee Count
2
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Pulmatrix
Pulmatrix is a publicly listed company on the NASDAQ with ticker symbol PULM in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Pulmatrix
Pulmatrix offers a comprehensive portfolio of products and services, including iSPERSE™, PUR3100, PUR1900, and PUR1800.
Innovative platform for pulmonary drug delivery to treat serious diseases.
Drug candidate for respiratory treatments in clinical development.
Pipeline drug for pulmonary disease management and innovation.
Advanced therapeutic in the company's pipeline for disease applications.
People of Pulmatrix
Unlock access to complete
Unlock access to complete
Funding Insights of Pulmatrix
Pulmatrix has successfully raised a total of $67.11M across 19 strategic funding rounds. The most recent funding activity was a Post-IPO round of $45 thousand completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pulmatrix
Pulmatrix has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and DARPA.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked |
Investor details for Pulmatrix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pulmatrix
Investment portfolio details for Pulmatrix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pulmatrix
Detailed financials for Pulmatrix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pulmatrix Comparisons
Peer comparison for Pulmatrix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pulmatrix
Pulmatrix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, InterMune, GEn1E and Verona Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Protein biologics are developed for treating rare diseases.
|
|
| Locked | Locked | Locked |
Precision medicines for lung-related diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies in pulmonology and orphan fibrotic diseases.
|
|
| Locked | Locked | Locked |
Developer of therapeutics for the treatment of inflammatory and rare diseases
|
|
| Locked | Locked | Locked |
Respiratory disease drugs for asthma and COPD are developed.
|
Detailed competitors of Pulmatrix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pulmatrix
Complete news archive for Pulmatrix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pulmatrix
Pulmatrix was founded in 2003 and raised its 1st funding round 1 year after it was founded.
Pulmatrix is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Pulmatrix is a funded company, having raised a total of $67.11M across 19 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Pulmatrix is 2.
Annual revenue of Pulmatrix is $7.81M as on Dec 31, 2024.
Developer of therapeutics for the treatment of respiratory diseases. The company offers inhaled cationic airway lining modulator drugs, which stimulate host defense mechanisms within the airway to treat and prevent influenza, rhinovirus, and chronic pulmonary diseases. The company uses an inhaled dry powder platform, iSPERSE (inhaled small particles easily respirable and emitted) to engineer particles with high dispersibility. Its product portfolio includes PUR1900, an inhaled anti-fungal product candidate for CF; PUR1500 for the treatment of idiopathic pulmonary fibrosis (IPF) which intends to suppress the fibrotic pathway at the site of disease in the lung interstitium and PUR0200 for COPD.
Pulmatrix's top competitors include aTyr Pharma, ReCode Therapeutics and GEn1E.
Pulmatrix offers iSPERSE™, PUR3100, PUR1900, and PUR1800.
Yes, Pulmatrix is publicly traded on NASDAQ under the ticker symbol PULM.
Pulmatrix has 10 investors. Key investors include NIH, HHS, DARPA, Arch Venture Partners, and 5AM Ventures.
The ticker symbol of Pulmatrix is PULM on NASDAQ.